Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

Prognostic relevance of MYD88 mutations in CLL: the jury is still out

(2015) P. Baliakas et al.   BLOOD

High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates

(2015) I. Bonzheim et al.   BLOOD

The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity inCXCR4Wild-typeandCXCR4WHIMmutated Waldenstrom macroglobulinaemia cells

(2015) Yang Cao et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clonal architecture ofCXCR4WHIM-like mutations in Waldenström Macroglobulinaemia

(2015) Lian Xu et al.   BRITISH JOURNAL OF HAEMATOLOGY

MYD88L265P andCXCR4mutations in lymphoplasmacytic lymphoma identify cases with high disease activity

(2015) Janine Schmidt et al.   BRITISH JOURNAL OF HAEMATOLOGY

Genomic Landscape of CXCR4 Mutations in Waldenstro m Macroglobulinemia

(2015) S. Poulain et al.   CLINICAL CANCER RESEARCH

Mutations driving CLL and their evolution in progression and relapse

(2015) Dan A. Landau et al.   NATURE

MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia

(2015) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

(2015) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival

(2015) T Nagao et al.   Blood Cancer Journal

C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma

(2014) A. M. Roccaro et al.   BLOOD

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia

(2014) S. P. Treon et al.   BLOOD

Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome

(2014) A. Martinez-Trillos et al.   BLOOD

MYD88L265P mutation contributes to the diagnosis of Bing Neel syndrome

(2014) Stéphanie Poulain et al.   BRITISH JOURNAL OF HAEMATOLOGY

Consequences of the recurrentMYD88L265Psomatic mutation for B cell tolerance

(2014) James Q. Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia

(2014) Y Cao et al.   LEUKEMIA

Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

(2014) L Xu et al.   LEUKEMIA

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia

(2014) S Weber et al.   Blood Cancer Journal

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia

(2013) Stéphanie Poulain et al.   AMERICAN JOURNAL OF HEMATOLOGY

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia

(2013) G. Yang et al.   BLOOD

MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance

(2013) M. Varettoni et al.   BLOOD

A new era for Waldenstrom macroglobulinemia: MYD88 L265P

(2013) S. P. Treon et al.   BLOOD

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

(2013) Z. R. Hunter et al.   BLOOD

MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

(2013) L. Xu et al.   BLOOD

The genomic landscape of chronic lymphocytic leukemia: clinical implications

(2013) Víctor Quesada et al.   BMC Medicine

Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia

(2013) Dan A. Landau et al.   CELL

The molecular profile of adult T-cell acute lymphoblastic leukemia: Mutations inRUNX1andDNMT3Aare associated with poor prognosis in T-ALL

(2013) Vera Grossmann et al.   GENES CHROMOSOMES & CANCER

Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications

(2013) Vera Grossmann et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia

(2013) C Jiménez et al.   LEUKEMIA

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients

(2013) S Jeromin et al.   LEUKEMIA

Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL

(2012) Wolfgang Kern et al.   BRITISH JOURNAL OF HAEMATOLOGY

Molecular pathogenesis of Waldenstrom's macroglobulinemia

(2012) E. Braggio et al.   HAEMATOLOGICA

IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas

(2012) N Gachard et al.   LEUKEMIA

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia

(2011) Wolfgang Kern et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia

(2009) Wolfgang Kern et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY